RESUMO
Primary plasma cell leukemia (pPCL) is an infrequent and aggressive plasma cell disorder. The prognosis is still very poor, and the optimal treatment remains to be established. A retrospective, multicentric, international observational study was performed. Patients from 9 countries of Latin America (LATAM) with a diagnosis of pPCL between 2012 and 2020 were included. 72 patients were included. Treatment was based on thalidomide in 15%, proteasome inhibitors (PI)-based triplets in 38% and chemotherapy plus IMIDs and/or PI in 29%. The mortality rate at 3 months was 30%. The median overall survival (OS) was 18 months. In the multivariate analysis, frontline PI-based triplets, chemotherapy plus IMIDs and/or PI therapy, and maintenance were independent factors of better OS. In conclusion, the OS of pPCL is still poor in LATAM, with high early mortality. PI triplets, chemotherapy plus IMIDs, and/or PI and maintenance therapy were associated with improved survival.
Assuntos
Leucemia Plasmocitária , Humanos , Leucemia Plasmocitária/diagnóstico , Leucemia Plasmocitária/epidemiologia , Leucemia Plasmocitária/terapia , Prognóstico , Bortezomib/uso terapêutico , Estudos Retrospectivos , Resultado do Tratamento , América Latina/epidemiologia , Agentes de Imunomodulação , DemografiaRESUMO
The study aim was to analyze incidence and presentation features of chronic lymphocytic leukemia (CLL) in Chile, in Amerindian population and in non-Native. Between 2012 and 2019, 912 patients were diagnosed, and 13 (1.4%) were Amerindian. The estimated incidence in Chilean population was 1.17/100,000 person per year, while in Amerindian, 0.09/100,000 person per year. Median age was 73 years. At diagnosis, 48, 27, and 25%, had low (0), intermediate (I/II) and high-risk (III/IV) disease on Rai classification. Diagnostic immunophenotypic Matutes score was ≥4 in 90%. Median follow-up was 37 months (range 2-87). 5-year OS was 56%, with median overall survival (OS) not reached. It was worse in men, ≥65 years, high-risk and those with increased prolymphocytes (CLL/PL). This study shows low incidence and worse OS in Chilean CLL patients, compared to those from European countries, despite similar clinical features. It also demonstrates that CLL is very uncommon in Amerindian population.
Assuntos
Leucemia Linfocítica Crônica de Células B , Idoso , Chile/epidemiologia , Humanos , Imunofenotipagem , Incidência , Leucemia Linfocítica Crônica de Células B/diagnóstico , Leucemia Linfocítica Crônica de Células B/epidemiologia , Contagem de Linfócitos , MasculinoRESUMO
Resumen La enfermedad por COVID-19 fue detectada a finales de 2019 en Wuhan, China. Debido a su rápida propagación fue declarada emergencia sanitaria de forma inicial y luego de identificar casos fuera de China con transmisión autóctona y caracterizado por una mortalidad considerablemente alta en países como Italia y España, fue declarada pandemia por la Organización Mundial de la Salud. Se ha evidenciado que los pacientes mayores y con antecedentes de enfermedades crónicas incluido el cáncer desarrollan una enfermedad severa, presentando mayor riesgo de mortalidad por SARS-CoV2/ COVID-19. Lo anterior es por supuesto especialmente importante en el manejo de pacientes con Mieloma Múltiple (MM), generando en el personal Médico nuevos desafíos, oportunidades de mejora y aprendizajes, que aporten al análisis riesgo-beneficio del tratamiento inmunodepresor en este tipo de patologías. El consenso tiene como objetivo brindar orientación sobre el manejo de pacientes con MM en estos momentos donde el profesional de la salud requiere información para llevar a cabo terapias eficientes en el cuidado del paciente.
Abstract COVID-19 disease was detected in late 2019 in Wuhan, China. Due to its rapid spread, it was initially declared a health emergency, but after cases with indigenous transmission were identified outside China, characterized by considerably high mortality in countries such as Italy and Spain, it was declared a pandemic by the World Health Organization. It has been shown that elderly patients with a history of chronic diseases, including cancer, develop a severe disease, presenting a higher risk of mortality from SARS-CoV2 / COVID-19. This becomes especially important in the management of patients with Multiple Myeloma (MM), generating new challenges, opportunities for improvement and learning opportunities in the health professionals, which will contribute to the risk-benefit analysis of immunosuppressive treatment for this type of pathology. The consensus aims to provide guidance for the management of patients with MM in these times when the health professional requires information to deliver efficient therapies in patient care.
Assuntos
Humanos , Consenso , COVID-19 , Mieloma Múltiplo , TerapêuticaRESUMO
The aim of this study was to describe clinical and survival characteristics of transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public and private healthcare facilities. We included 1293 patients diagnosed between 2010 and 2018. A great disparity in outcomes and survival between both groups was observed. Late diagnosis and low access to adequate frontline therapy and ASCT in public institutions probably explain these differences. Patients treated with novel drug induction protocols, followed by autologous stem cell transplantation (ASCT) and maintenance, have similar overall survival compared to that published internationally.
Assuntos
Transplante de Células-Tronco Hematopoéticas , Mieloma Múltiplo , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Humanos , América Latina/epidemiologia , Mieloma Múltiplo/diagnóstico , Mieloma Múltiplo/epidemiologia , Mieloma Múltiplo/terapia , Transplante Autólogo , Resultado do TratamentoRESUMO
BACKGROUND: Primary plasma cell leukemia (pPCL) is uncommon, aggressive and has a different biology than multiple myeloma (MM). AIM: To report the features of patients with pPCL. MATERIAL AND METHODS: Review of databases of the Hematology Department and the Hematology laboratory. RESULTS: Of 178 patients with monoclonal gammopathies, five (2.8%) patients aged 33 to 64 years (three females) had a pPCL. The mean hemoglobin was 7.3 g/dL, the mean white blood cell count was 52,500/mm3, with 58% plasma cells, and the mean platelet count was 83,600/mm3. The mean bone marrow infiltration was 89%, LDH was 2,003 IU/L, serum calcium was 13 mg/dL, and creatinine 1.5 mg/dL. Two patients had bone lesions. Three were IgG, one IgA lambda and one lambda light chain. CD20 was positive in one, CD56 was negative in all and CD117 was negative in 3 cases. By conventional cytogenetic analysis, two had a complex karyotype. By Fluorescence in situ Hybridization, one was positive for TP53 and another for t (11; 14). One patient did not receive any treatment, three patients received VTD PACE and one CTD. None underwent transplant. Three patients are alive. The mean survival was 14 months. CONCLUSIONS: These patients with pPCL were younger and had a more aggressive clinical outcome than in multiple myeloma.
Assuntos
Leucemia Plasmocitária/epidemiologia , Leucemia Plasmocitária/genética , Adulto , Contagem de Células Sanguíneas , Cálcio/sangue , Chile/epidemiologia , Creatinina/sangue , Análise Citogenética , Feminino , Citometria de Fluxo/métodos , Humanos , Hibridização in Situ Fluorescente , Leucemia Plasmocitária/patologia , Leucemia Plasmocitária/terapia , Masculino , Pessoa de Meia-Idade , Paraproteinemias/epidemiologia , Paraproteinemias/genética , Paraproteinemias/patologia , Estudos Retrospectivos , Análise de Sobrevida , Resultado do TratamentoRESUMO
Background: Primary plasma cell leukemia (pPCL) is uncommon, aggressive and has a different biology than multiple myeloma (MM). Aim: To report the features of patients with pPCL. Material and Methods: Review of databases of the Hematology Department and the Hematology laboratory. Results: Of 178 patients with monoclonal gammopathies, five (2.8%) patients aged 33 to 64 years (three females) had a pPCL. The mean hemoglobin was 7.3 g/dL, the mean white blood cell count was 52,500/mm3, with 58% plasma cells, and the mean platelet count was 83,600/mm3. The mean bone marrow infiltration was 89%, LDH was 2,003 IU/L, serum calcium was 13 mg/dL, and creatinine 1.5 mg/dL. Two patients had bone lesions. Three were IgG, one IgA lambda and one lambda light chain. CD20 was positive in one, CD56 was negative in all and CD117 was negative in 3 cases. By conventional cytogenetic analysis, two had a complex karyotype. By Fluorescence in situ Hybridization, one was positive for TP53 and another for t (11; 14). One patient did not receive any treatment, three patients received VTD PACE and one CTD. None underwent transplant. Three patients are alive. The mean survival was 14 months. Conclusions: These patients with pPCL were younger and had a more aggressive clinical outcome than in multiple myeloma.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Leucemia Plasmocitária/genética , Leucemia Plasmocitária/epidemiologia , Paraproteinemias/genética , Paraproteinemias/patologia , Paraproteinemias/epidemiologia , Contagem de Células Sanguíneas , Leucemia Plasmocitária/patologia , Leucemia Plasmocitária/terapia , Análise de Sobrevida , Chile/epidemiologia , Cálcio/sangue , Estudos Retrospectivos , Resultado do Tratamento , Hibridização in Situ Fluorescente , Creatinina/sangue , Análise Citogenética , Citometria de Fluxo/métodosRESUMO
Background: Trauma is an important cause of death among young adults. Aim: To determine the characteristics, treatments and evolution of trauma patients admitted to an intensive care unit (ICU) of a public hospital in Santiago, Chile. Material and Methods: All polytrauma (PT) and severely traumatized (ST) patients admitted to ICU were included. We recorded the type of trauma along with demographic and hemodynamic variables, treatments and complications. The evolution and treatments received by PT and ST patients were compared. Results: We recorded data from 72 patients aged 43 ± 21 years (93% males). Sixty two percent were PT and 24% had penetrating injuries. TBI (Trauma Brain Injury) was the most common trauma. On admission, acute Physiology and Chronic Health Evaluation II (APACHE II) score was 18.7 + 7.3, and Injury Severity Score (ISS) was 32.8 + 20.1. ICU stay was 7.8 + 6 days. Sixty seven per cent of patients required surgery and 58% received blood transfusions. No differences were found between PT and ST. ICU and hospital mortality rates were 15 and 25% respectively. Conclusions: The characteristics and evolution of PT and ST of this series of patients are similar to those described abroad. Mortality was in agreement with ISS and APACHE II scores.
Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Ferimentos e Lesões , APACHE , Transfusão de Sangue , Chile/epidemiologia , Traumatismos Craniocerebrais/epidemiologia , Traumatismos Craniocerebrais/mortalidade , Traumatismos Craniocerebrais/terapia , Hemodinâmica/efeitos dos fármacos , Mortalidade Hospitalar , Hospitalização/estatística & dados numéricos , Hospitais Gerais , Escala de Gravidade do Ferimento , Unidades de Terapia Intensiva , Estudos Prospectivos , Resultado do Tratamento , Ferimentos e Lesões/epidemiologia , Ferimentos e Lesões/mortalidade , Ferimentos e Lesões/terapiaRESUMO
BACKGROUND: Trauma is an important cause of death among young adults. AIM: To determine the characteristics, treatments and evolution of trauma patients admitted to an intensive care unit (ICU) of a public hospital in Santiago, Chile. MATERIAL AND METHODS: All polytrauma (PT) and severely traumatized (ST) patients admitted to ICU were included. We recorded the type of trauma along with demographic and hemodynamic variables, treatments and complications. The evolution and treatments received by PT and ST patients were compared. RESULTS: We recorded data from 72 patients aged 43 ± 21 years (93% males). Sixty two percent were PT and 24% had penetrating injuries. TBI (Trauma Brain Injury) was the most common trauma. On admission, acute Physiology and Chronic Health Evaluation II (APACHE II) score was 18.7 + 7.3, and Injury Severity Score (ISS) was 32.8 + 20.1. ICU stay was 7.8 + 6 days. Sixty seven per cent of patients required surgery and 58% received blood transfusions. No differences were found between PT and ST. ICU and hospital mortality rates were 15 and 25% respectively. CONCLUSIONS: The characteristics and evolution of PT and ST of this series of patients are similar to those described abroad. Mortality was in agreement with ISS and APACHE II scores.